OpenAI launches ChatGPT Health to analyze medical records

FDA releases 10 guiding principles for AI use in drug development

FDA, in collaboration with the European Medicines Agency, has published 10 principles to help guide pharmaceutical companies using artificial intelligence to develop drug, biological, and medical devices.

Mayo develops AI tool that predicts prostate cancer recurrence

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department of Radiation Oncology developed the PSA Control Tower, an intelligent monitoring tool designed to support clinicians in keeping a close, ongoing watch over patients after treatment.

January 16, 2026

Vol.52 No.02

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

Immune-checkpoint inhibitors (ICIs) transformed treatment paradigms in dozens of malignancies, yet oncologists still confront a deceptively simple question at every consult: Will this individual patient benefit and at what cost?

January 09, 2026

Vol.52 No.1

By Ofer Sharon, Michal Harel and Yehonatan Elon

Drugs & Targets

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

SOPHiA GENETICS and The University of Texas MD Anderson Cancer Center have entered into a collaboration to accelerate data-driven cancer care through new tools that can accurately analyze, interpret, and translate diagnostic results into clinical practice.

January 09, 2026

Vol.52 No.1

Regulatory News

ESMO publishes guidances on AI tools for clinicians, patients, and researchers
Says one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”

The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?

HHS issues AI strategy for internal agency operations

HHS has issued its AI strategy—“the first step” in making a “whole-of-department transformation” towards the use of artificial intelligence in public health, health care delivery, biomedical research, human services, and agency operations.

December 12, 2025

Vol.51 No.45

By Sara Willa Ernst

OpenAI launches ChatGPT Health to analyze medical records

YOU MAY BE INTERESTED IN

FDA releases 10 guiding principles for AI use in drug development

Mayo develops AI tool that predicts prostate cancer recurrence

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

ESMO publishes guidances on AI tools for clinicians, patients, and researchers
Says one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”

HHS issues AI strategy for internal agency operations

Renew today!

Subscriber content

Never miss an issue!

Login

OpenAI launches ChatGPT Health to analyze medical records

YOU MAY BE INTERESTED IN

FDA releases 10 guiding principles for AI use in drug development

Mayo develops AI tool that predicts prostate cancer recurrence

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

ESMO publishes guidances on AI tools for clinicians, patients, and researchersSays one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”

HHS issues AI strategy for internal agency operations

Never miss an issue!

Login

ESMO publishes guidances on AI tools for clinicians, patients, and researchers
Says one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”